Approved revisions

View list of: Pages whose approved revision is not their latest | Unapproved pages | All pages with an approved revision | Pages with invalid approvals

Showing below up to 50 results in range #201 to #250.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. 16. Synthesis of biologically active molecules from amino acids (revision 1388, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  2. 16. T-helper cell mediated macrophage activation, delayed type hypersensitivity (revision 1519, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  3. 16A. Clinical symptoms of insufficient blood supply in territory of carotid and vertebral artery (+ the anterior circulation) (revision 2240, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  4. 16B. Differential diagnosis of short-term loss of consciousness (revision 2241, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  5. 17. Acute and chronic pancreatitis. Tumours of the pancreas (revision 95, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  6. 17. Adenocarcinoma of the gall bladder with multiple liver metastases (revision 4634, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  7. 17. Adrenergic receptor agonists (revision 1993, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  8. 17. Benign and malignant tumours of the paranasal sinuses (revision 3097, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  9. 17. CLL or SLL infiltration in lymph node (revision 4706, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  10. 17. Cancer of the pancreas and the liver (revision 5055, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  11. 17. Concentric hypertrophy of the left ventricle of the heart (revision 586, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  12. 17. Development of the brainstem and the cerebellum (revision 1659, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  13. 17. Epidemiological indicators II: definition and measures of relative risk and odds ratio (revision 1081, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  14. 17. Epidemiology and prevention of liver-, pancreas- and gastric cancer (revision 1162, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  15. 17. Genomics and epigenetics in public health. Nutrigenomics (revision 1119, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  16. 17. Glandular cystic hyperplasia of the endometrium (revision 4494, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  17. 17. Imaging of the urinary system. Indications, diagnostic strategy. Renal inflammatory diseases, nephrolithiasis. (revision 5427, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  18. 17. Immunological memory, primary and secondary immune response (revision 1520, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  19. 17. Laboratory findings in inflammatory disorders (revision 4094, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  20. 17. Nervous system II (revision 1592, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  21. 17. Nucleotide synthesis and degradation (revision 1390, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  22. 17. Pathology of obesity and diabetes (revision 243, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  23. 17. Portal hypertension (revision 1864, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  24. 17. The basic structure and metabolism of haemoglobin and the metabolism of iron (revision 1231, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  25. 17. Tissue hypoxia, ischemia, reperfusion and tissue metabolism (revision 1709, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  26. 17A. Types and etiology of unconsciousness. Coma (revision 2242, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  27. 17B. Status epilepticus (revision 2243, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  28. 18. Adrenergic receptor antagonists (alpha blockers and beta blockers) (revision 1994, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  29. 18. Ascites and hepatorenal syndrome (revision 1865, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  30. 18. Causes of atrophy; general gross morphology and microscopical characteristics. Pathomechanism of atrophy. Hypoplasia, aplasia, agenesia. Osteoporosis. (revision 246, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  31. 18. Colorectal cancer (revision 5060, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  32. 18. Describe the two pathways involved in the initiation of blood coagulation (revision 4134, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  33. 18. Development of the diencephalon and the telencephalon. Development of the commissural pathways and the fornix (revision 1660, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  34. 18. Diffuse large B-cell lymphoma (DLBCL) (revision 4707, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  35. 18. Dilatative hypertrophy of the left ventricle of the heart (revision 4431, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  36. 18. Epidemiology and prevention of head and neck cancers and skin cancers (revision 1163, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  37. 18. Genes and chromosomes (revision 1391, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  38. 18. Laboratory diagnosis of malignant hematologic disorders; complete blood count and flow cytometry (revision 4102, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  39. 18. Molecular basics of carcinogenesis (revision 1120, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  40. 18. Nervous system III (revision 1595, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  41. 18. Obstruction of the nasal airway, rhinitis (forms of rhinitis, except allergic rhinitis) (revision 3102, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  42. 18. Onco-uroradiology: Adrenal and renal masses. Masses of the urinary bladder, the prostate and the testis. Imaging techniques and strategy. (revision 5567, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  43. 18. Pancreatic carcinoma (revision 719, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  44. 18. Pathogenesis of coronary insufficiency. Risk factors (revision 1712, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  45. 18. Pulmonary oedema (revision 4495, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  46. 18. Renal failure, uraemia. Congenital malformations and cystic diseases of the kidney (revision 96, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  47. 18. Standardization (revision 1082, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  48. 18. Suppression of the immune response (revision 1524, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  49. 18A. Migraine and other primary headaches (revision 2244, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  50. 18B. Types of disturbances of urinary bladder innervation (revision 5412, approved by 127.0.0.1 on 26 November 2024 at 10:57)

View ( | ) (20 | 50 | 100 | 250 | 500)